The genetic contribution of the NO system at the glutamatergic post-synapse to schizophrenia: Further evidence and meta-analysis

European Neuropsychopharmacology

Volumn 24, Issue 1, 2014, Pages 65-85

  Weber, H ^a,b   Klamer, D ^c   Freudenberg, F ^a   Kittel Schneider, S ^a   Rivero, O ^a,d   Scholz, C J ^b   Volkert, J ^a   Kopf, J ^a   Heupel, J ^a   Herterich, S ^b   Adolfsson, R ^e   Alttoa, A ^a   Post, A ^a   Grussendorf H ^a   Kramer, A ^a   Gessner, A ^a   Schmidt, B ^a   Hempel, S ^a   Jacob, C P ^a   Sanjuan J ^d   Molto M D ^d   Lesch, K P ^a,b   Freitag, C M ^f   Kent, L ^g   Reif, A ^a,b   more..

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF VALENCIA   (Spain)

^e UMEÅ UNIVERSITY   (Sweden)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Association; Glutamate; Nitric oxide; Post synapse; Prefrontal cortex; Schizophrenia

Indexed keywords

GLUTAMIC ACID; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PDZ PROTEIN;

ALLELE; ALTERNATIVE RNA SPLICING; ARTICLE; AUTOPSY; BINDING SITE; BRAIN TISSUE; CHROMOSOME 1; CHROMOSOME 12; CHROMOSOME 17; CHROMOSOME 3; CONTROLLED STUDY; FOREBRAIN; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; META ANALYSIS; PDZ DOMAIN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA; SYNAPSE; SYNAPTIC TRANSMISSION;

ASSOCIATION; GLUTAMATE; NITRIC OXIDE; POST-SYNAPSE; PREFRONTAL CORTEX; SCHIZOPHRENIA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; COMPUTATIONAL BIOLOGY; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; PROMOTER REGIONS, GENETIC; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 84892477481     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.09.005     Document Type: Article

References (50)

1. Aberg K., Adkins D.E., Liu Y., McClay J.L., Bukszar J., Jia P., Zhao Z., Perkins D., Stroup T.S., Lieberman J.A., Sullivan P.F., van den Oord E.J. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics Journal 2010, 12:165-172.
2. Baba H., Suzuki T., Arai H., Emson P.C. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 2004, 15:677-680.
3. Bernstein H.G., Keilhoff G., Steiner J., Dobrowolny H., Bogerts B. Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy. CNS & Neurological Disorders - Drug Targets 2011, 10:792-807.
4. Brzustowicz L.M. NOS1AP in schizophrenia. Current Psychiatry Reports 2008, 10:158-163.
5. Brzustowicz L.M., Simone J., Mohseni P., Hayter J.E., Hodgkinson K.A., Chow E.W., Bassett A.S. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. American Journal of Human Genetics 2004, 74:1057-1063.
6. Costain G., Ho A., Crawley A.P., Mikulis D.J., Brzustowicz L.M., Chow E.W., Bassett A.S. Reduced gray matter in the anterior cingulate gyrus in familial schizophrenia: a preliminary report. Schizophrenia Research 2010, 122:81-84.
7. Cui, H., Nishiguchi, N., Yanagi, M., Fukutake, M., Mouri, K., Kitamura, N., Hashimoto, T., Shirakawa, O., Hishimoto, A., 2010. A putative cis-acting polymorphism in the NOS1 gene is associated with schizophrenia and NOS1 immunoreactivity in the postmortem brain. Schizophr Research.
8. Delorme R., Betancur C., Scheid I., Anckarsater H., Chaste P., Jamain S., Schuroff F., Nygren G., Herbrecht E., Dumaine A., Mouren M.C., Rastam M., Leboyer M., Gillberg C., Bourgeron T. Mutation screening of NOS1AP gene in a large sample of psychiatric patients and controls. BMC Medical Genetics 2010, 11:108.
9. Donohoe G., Walters J., Morris D.W., Quinn E.M., Judge R., Norton N., Giegling I., Hartmann A.M., Moller H.J., Muglia P., Williams H., Moskvina V., Peel R., O'Donoghue T., Owen M.J., O'Donovan M.C., Gill M., Rujescu D., Corvin A. Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Archives of General Psychiatry 2009, 66:1045-1054.
10. Doucet, M.V., Levine, H., Dev, K.K., Harkin, A., 2013. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology.
11. Fallin M.D., Lasseter V.K., Avramopoulos D., Nicodemus K.K., Wolyniec P.S., McGrath J.A., Steel G., Nestadt G., Liang K.Y., Huganir R.L., Valle D., Pulver A.E. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. American Journal of Human Genetics 2005, 77:918-936.
12. Fang C., Tang W., Tang R.Q., Wang L., Zhou G.Q., Huang K., Li X.W., Feng G.Y., He M., Du L.Z., Zhu S.M., Xing Y.L., Sang H., He L., Shi Y.Y. Family-based association studies of CAPON and schizophrenia in the Chinese Han population. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32:1210-1213.
13. Fang M., Jaffrey S.R., Sawa A., Ye K., Luo X., Snyder S.H. Dexras1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON. Neuron 2000, 28:183-193.
14. Fejgin K., Palsson E., Wass C., Svensson L., Klamer D. Nitric oxide signaling in the medial prefrontal cortex is involved in the biochemical and behavioral effects of phencyclidine. Neuropsychopharmacology 2008, 33:1874-1883.
15. Greenwood T.A., Lazzeroni L.C., Murray S.S., Cadenhead K.S., Calkins M.E., Dobie D.J., Green M.F., Gur R.E., Gur R.C., Hardiman G., Kelsoe J.R., Leonard S., Light G.A., Nuechterlein K.H., Olincy A., Radant A.D., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Freedman R., Braff D.L. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. American Journal of Psychiatry 2011, 168:930-946.
16. Hallak J.E., Maia-de-Oliveira J.P., Abrao J., Evora P.R., Zuardi A.W., Crippa J.A.S., Belmonte-de-Abreu P., Baker G.B., Dursun S.M. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside. JAMA Psychiatry 2013, 70:668-676.
17. Haraguchi K., Satoh K., Yanai H., Hamada F., Kawabuchi M., Akiyama T. The hDLG-associated protein DAP interacts with dynein light chain and neuronal nitric oxide synthase. Genes to Cells 2000, 5:905-911.
18. Husted J.A., Ahmed R., Chow E.W., Brzustowicz L.M., Bassett A.S. Childhood trauma and genetic factors in familial schizophrenia associated with the NOS1AP gene. Schizophrenia Research 2010, 121:187-192.
19. Jaffrey S.R., Benfenati F., Snowman A.M., Czernik A.J., Snyder S.H. Neuronal nitric-oxide synthase localization mediated by a ternary complex with synapsin and CAPON. Proceedings of the National Academy of Sciences of theUnited States of America 2002, 99:3199-3204.
20. Jaffrey S.R., Snowman A.M., Eliasson M.J., Cohen N.A., Snyder S.H. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 1998, 20:115-124.
21. Kawohl W., Giegling I., Mavrogiorgou P., Pogarell O., Mulert C., Moller H.J., Hegerl U., Rujescu D., Juckel G. Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. International Journal of Neuropsychopharmacol 2008, 11:477-483.
22. Kiss J.P., Vizi E.S. Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends in Neuroscience 2001, 24:211-215.
23. Kopf J., Schecklmann M., Hahn T., Dieler A.C., Herrmann M.J., Fallgatter A.J., Reif A. NOS1 ex1f-VNTR polymorphism affects prefrontal oxygenation during response inhibition tasks. Human Brain Mapping 2012, 33:2561-2571.
24. Kremeyer B., Garcia J., Kymalainen H., Wratten N., Restrepo G., Palacio C., Miranda A.L., Lopez C., Restrepo M., Bedoya G., Brzustowicz L.M., Ospina-Duque J., Arbelaez M.P., Ruiz-Linares A. Evidence for a role of the NOS1AP (CAPON) gene in schizophrenia and its clinical dimensions: an association study in a South American population isolate. Human Heredity 2009, 67:163-173.
25. Liou Y.J., Hong C.J., Liu H.C., Liu C.Y., Liu T.Y., Chen I.C., Tsai S.J. No association between the neuronal nitric oxide synthase gene polymorphism and Alzheimer Disease. American Journal of Medical Genetics 2002, 114:687-688.
26. Miranda A., Garcia J., Lopez C., Gordon D., Palacio C., Restrepo G., Ortiz J., Montoya G., Cardeno C., Calle J., Lopez M., Campo O., Bedoya G., Ruiz-Linares A., Ospina-Duque J. Putative association of the carboxy-terminal PDZ ligand of neuronal nitric oxide synthase gene (CAPON) with schizophrenia in a Colombian population. Schizophrenia Research 2006, 82:283-285.
27. Navarro-Lerida I., Martinez Moreno M., Roncal F., Gavilanes F., Albar J.P., Rodriguez-Crespo I. Proteomic identification of brain proteins that interact with dynein light chain LC8. Proteomics 2004, 4:339-346.
28. Nicodemus K.K., Law A.J., Radulescu E., Luna A., Kolachana B., Vakkalanka R., Rujescu D., Giegling I., Straub R.E., McGee K., Gold B., Dean M., Muglia P., Callicott J.H., Tan H.Y., Weinberger D.R. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Archives of General Psychiatry 2010, 67:991-1001.
29. Nicodemus K.K., Marenco S., Batten A.J., Vakkalanka R., Egan M.F., Straub R.E., Weinberger D.R. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Molecular Psychiatry 2008, 13:873-877.
30. O'Donoghue T., Morris D.W., Fahey C., Da Costa A., Foxe J.J., Hoerold D., Tropea D., Gill M., Corvin A., Donohoe G. A NOS1 variant implicated in cognitive performance influences evoked neural responses during a high density EEG study of early visual perception. Human Brain Mapping 2012, 33:1202-1211.
31. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., Hamshere M., Carroll L., Georgieva L., Dwyer S., Holmans P., Marchini J.L., Spencer C.C., Howie B., Leung H.T., Hartmann A.M., Moller H.J., Morris D.W., Shi Y., Feng G., Hoffmann P., Propping P., Vasilescu C., Maier W., Rietschel M., Zammit S., Schumacher J., Quinn E.M., Schulze T.G., Williams N.M., Giegling I., Iwata N., Ikeda M., Darvasi A., Shifman S., He L., Duan J., Sanders A.R., Levinson D.F., Gejman P.V., Cichon S., Nothen M.M., Gill M., Corvin A., Rujescu D., Kirov G., Owen M.J., Buccola N.G., Mowry B.J., Freedman R., Amin F., Black D.W., Silverman J.M., Byerley W.F., Cloninger C.R. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genetics 2008, 40:1053-1055.
32. Okumura T., Okochi T., Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Tsunoka T., Ujike H., Inada T., Ozaki N., Iwata N. No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population. NeuroMolecular Medicine 2009, 11:123-127.
33. Palsson E., Lowry J., Klamer D. Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia. Psychopharmacology (Berl) 2010, 212:643-651.
34. Puri V., McQuillin A., Choudhury K., Datta S., Pimm J., Thirumalai S., Krasucki R., Lawrence J., Quested D., Bass N., Moorey H., Morgan J., Punukollu B., Kandasami G., Curtis D., Gurling H. Fine mapping by genetic association implicates the chromosome 1q23.3 gene UHMK1, encoding a serine/threonine protein kinase, as a novel schizophrenia susceptibility gene. Biological Psychiatry 2007, 61:873-879.
35. Puri V., McQuillin A., Thirumalai S., Lawrence J., Krasucki R., Choudhury K., Datta S., Kerwin S., Quested D., Bass N., Pimm J., Lamb G., Moorey H., Kandasami G., Badacsonyi A., Kelly K., Morgan J., Punukollu B., Nadeem H., Curtis D., Gurling H.M. Failure to confirm allelic association between markers at the CAPON gene locus and schizophrenia in a British sample. Biological Psychiatry 2006, 59:195-197.
36. Reif A., Herterich S., Strobel A., Ehlis A.C., Saur D., Jacob C.P., Wienker T., Topner T., Fritzen S., Walter U., Schmitt A., Fallgatter A.J., Lesch K.P. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Molecular Psychiatry 2006, 286-300.
37. Reif A., Kiive E., Kurrikoff T., Paaver M., Herterich S., Konstabel K., Tulviste T., Lesch K.P., Harro J. A functional NOS1 promoter polymorphism interacts with adverse environment on functional and dysfunctional impulsivity. Psychopharmacology (Berl) 2011.
38. Riley B., Thiselton D., Maher B.S., Bigdeli T., Wormley B., McMichael G.O., Fanous A.H., Vladimirov V., O'Neill F.A., Walsh D., Kendler K.S. Replication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample. Molecular Psychiatry 2010, 15:29-37.
39. Rodriguez-Crespo I., Yelamos B., Roncal F., Albar J.P., Ortiz de Montellano P.R., Gavilanes F. Identification of novel cellular proteins that bind to the LC8 dynein light chain using a pepscan technique. FEBS Letters 2001, 503:135-141.
40. Rose E.J., Greene C., Kelly S., Morris D.W., Robertson I.H., Fahey C., Jacobson S., O'Doherty J., Newell F.N., McGrath J., Bokde A., Garavan H., Frodl T., Gill M., Corvin A.P., Donohoe G. The NOS1 variant rs6490121 is associated with variation in prefrontal function and grey matter density in healthy individuals. Neuroimage 2012, 60:614-622.
41. Saur D., Vanderwinden J.M., Seidler B., Schmid R.M., De Laet M.H., Allescher H.D. Single-nucleotide promoter polymorphism alters transcription of neuronal nitric oxide synthase exon 1c in infantile hypertrophic pyloric stenosis. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:1662-1667.
42. Saviouk V., Moreau M.P., Tereshchenko I.V., Brzustowicz L.M. Association of synapsin 2 with schizophrenia in families of Northern European ancestry. Schizophrenia Research 2007, 96:100-111.
43. Shinkai T., Ohmori O., Hori H., Nakamura J. Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Molecular Psychiatry 2002, 7:560-563.
44. Silberberg G., Ben-Shachar D., Navon R. Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder. American Journal of Medical Genetics Part B Neuropsychiatric Genetics 2010, 153B:1318-1328.
45. Tang W., Huang K., Tang R., Zhou G., Fang C., Zhang J., Du L., Feng G., He L., Shi Y. Evidence for association between the 5' flank of the NOS1 gene and schizophrenia in the Chinese population. International Journal of Neuropsychopharmacology 2008, 11:1063-1071.
46. Wang J., Ma X.H., Xiang B., Wu J.Y., Wang Y.C., Deng W., Li M.L., Wang Q., He Z.L., Li T. Association study of NOS1 gene polymorphisms and schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012, 29:459-463.
47. Wratten N.S., Memoli H., Huang Y., Dulencin A.M., Matteson P.G., Cornacchia M.A., Azaro M.A., Messenger J., Hayter J.E., Bassett A.S., Buyske S., Millonig J.H., Vieland V.J., Brzustowicz L.M. Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. American Journal of Psychiatry 2009, 166:434-441.
48. Xu B., Wratten N., Charych E.I., Buyske S., Firestein B.L., Brzustowicz L.M. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Medicine 2005, 2:e263.
49. Zheng Y., Li H., Qin W., Chen W., Duan Y., Xiao Y., Li C., Zhang J., Li X., Feng G., He L. Association of the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. Biochemical and Biophysical Research Communications 2005, 328:809-815.
50. Zoubovsky S.P., Pogorelov V.M., Taniguchi Y., Kim S.H., Yoon P., Nwulia E., Sawa A., Pletnikov M.V., Kamiya A. Working memory deficits in neuronal nitric oxide synthase knockout mice: potential impairments in prefrontal cortex mediated cognitive function. Biochemical and Biophysical Research Communications 2011, 408:707-712.